UK-headquartered IONTAS Limited, a company specialising in the discovery and optimisation of fully human antibodies, has published a research paper in Nature Communications in collaboration with the Technical University of Denmark and the Instituto Clodomiro Picado of the University of Costa Rica describing the development of a panel of human antibodies that neutralise elements of black mamba snake toxin in an in-vivo model. Snakebite envenoming has recently been introduced on the World Health Organization’s list of neglected tropical diseases due to its high disease burden.
The proof of concept research described in Nature Communications identifies key components in the black mamba’s venom that contribute to venom toxicity, which include dendrotoxins. Human antibodies were generated to these dendrotoxins using IONTAS Phage Display Technology and mixtures of IgG-formatted human antibodies were then shown to protect mice from dendrotoxin-mediated neurotoxicity in vivo.
For further information about IONTAS Limited visit www.iontas.co.uk
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!